-
-
State of the Heart
-
Click here to download the scietific program.
PRELIMINARY SCIENTIFIC PROGRAM Time Wednesday February 17, 2010 11.30 - 13.00 Arrivals, registration and Lunch 13.00 – 13.10 Welcome address – Lars Wallentin Risk stratification and new pharmacological solutions
Chairman: M Ezekowitz, E Swahn13.10 – 13.30 Identification of AF and risk for stroke in AF – Mårten Rosenqvist 13.30 – 13.50 Risk stratification for treatment in ACS – B Lindahl 13.50 – 14.10 Pharmacology of new coagulation inhibitors – A Siegbahn 14.10 – 14.30 Pharmacology of new platelet inhibitors – S Husted 14.30 – 14.50 Pharmacogenetics of coagulation and platelet inhibition – M Wadelius 14.50 – 15.10 Discussion 15.10 – 15.40 Coffee Oral pharmacological treatments to prevent stroke in AF
Chairmen: S Husted, V Frykman15.40 – 16.00 Optimized oral anticoagulation – P Svensson 16.00 – 16.20 Review of new alternative agents – R De Caterina 16.20 – 17.00 New results with oral thrombin inhibition – M Ezekowitz & L Wallentin 17.00 – 17.30 Discussion – pros and cons with the different alternatives 19.00 Dinner PRELIMINARY SCIENTIFIC PROGRAM Time Thursday February 18, 2010 Oral pharmacological treatments in ACS
Chairmen: F van de Werf, E Ståhle08.10 – 08.30 Optimized use of current alternatives – F W A Verheugt 08.30 – 08.50 New irreversible platelet inhibitors – D Erlinge 08.50 – 09.30 New reversible platelet inhibitors – R Harrington & L Wallentin 09.30 – 10.00 Discussion – pros and cons with the new alternatives 10.00 – 10.30 Coffee Forthcoming challenges in the treatment of AF and ACS
Chairman: R Harrington, C Linde10.30 – 10.50 Combinations of coagulation and platelet inhibitors in AF – K Huber 10.50 – 11.20 Combinations of coagulation and platelet inhibitors in ACS – J Oldgren 11.20 – 11.40 Reperfusion treatment in the new environment – F van de Werf 11.40 – 12.10 Real life antithrombotic treatment in ACS – T Jernberg 12.00 – 12.20 Real life antithrombotic treatment at and by PCI – S James 12.20 – 12.50 Discussion – challenges and solutions with combination treatments 12.50 – 13.00 Concluding remarks – Lars Wallentin 13.00 - 14.00 Departures and Grab to go lunch
-
